3:36 PM Abstract No. 66 Prostate artery embolization for patients with prostates size smaller than 50 g: a single-center experience with 1-year follow-up

Abstract

To evaluate the efficacy and quality of life (QOL) impact of prostatic artery embolization (PAE) for the treatment of benign prostatic hyperplasia (BPH) for prostates size < 50 g. 27 patients who underwent PAE for BPH with prostate size < 50 g from June 2014 to May 2019 were evaluated as part of a retrospective analysis. Mean patient age was 68 years, mean prostate volume was 39.2 g, mean pre procedure IPSS, QOL and PVR were 25.7, 5.1 and 92.4 mL. Patients were evaluated at 3, 6 and 12 months following after PAE. Patients with active urinary tract infection (UTI), history of recurrent infection, renal failure, severe atherosclerosis and no follow-up at 3 or 6 months were excluded from the analysis. Adverse events were recorded using the Clavien-Dindo classification. Three months after PAE, mean IPSS was 11.3 (↓56%, n = 25, P <0.001), mean QOL was 2 (↓61%, n = 27, P <0.001) and mean prostate volume was 29.8 g (↓24%, n = 25, P <0.001). There was nearly a 40% decrease in mean PVR which improved from 152.7 to 92.3 mL. At 6-month follow-up mean IPSS was 9.3 (↓64%, n = 9, P <0.001) and mean QOL was 2 (↓61%, n = 11, P <0.001). At 12 months, mean IPSS was 10.3 (↓60%, n = 8, P <0.001) and mean QOL was 2.3 (↓55%, n = 8, P = 0.001). Sixteen grade I events occurred. One grade II event occurred, UTI, treated with antibiotics. PAE achieved a clinically and statistically significant reduction in prostate size, IPSS score and improved QOL in patients with prostates < 50 g. These findings support PAE as an efficacious treatment option for BPH in patients with smaller prostates with a favorable safety profile compared to conventional surgical options.